The European Medicines Agency (EMA) has published a presentation outlining the importance of new approach methodologies (NAMs) in drug development, a move that signals the agency's growing emphasis on alternatives to traditional animal testing. The presentation, dated 7 August 2026, was authored by S. Ponzano and is part of the agency's ongoing efforts to promote the use of NAMs across the pharmaceutical sector.
NAMs refer to a range of techniques, including in vitro models, computational methods, and organ-on-chip technologies, that aim to improve the predictability of drug safety and efficacy while reducing reliance on animal models. The EMA's presentation is expected to highlight how these methods can accelerate drug development, lower costs, and provide more human-relevant data, aligning with broader EU policy goals to phase out animal testing where scientifically possible.
The document comes amid a wider regulatory push within the EU to integrate NAMs into the assessment of medicines. The European Commission has previously endorsed the concept in its strategies on chemicals and pharmaceuticals, and the EMA has been actively engaging with stakeholders through workshops and guidance updates. This presentation likely serves as an educational tool for regulators, industry, and academia, explaining the scientific rationale and potential applications of NAMs.
For pharmaceutical companies, the adoption of NAMs could reduce the time and expense associated with preclinical testing, potentially speeding up the delivery of new therapies to patients. However, it also poses challenges, including the need for validation and regulatory acceptance of novel methods, which may require significant investment in new technologies and expertise. Regulators, meanwhile, must balance the promise of NAMs with the need to ensure robust safety assessments, particularly for complex biologics and vaccines.
Patient groups stand to benefit from faster access to innovative treatments, but they also rely on rigorous safety standards, which NAMs must uphold. The EMA's presentation is likely to reassure stakeholders that the agency is committed to maintaining high regulatory standards while embracing scientific progress.
As the EU moves towards a more integrated approach to NAMs, the EMA's role in setting guidelines and fostering collaboration will be crucial. The presentation, while not a formal policy document, underscores the agency's proactive stance in shaping the future of regulatory science.